Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.51 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29740503 | 0.97 | DPP8 (0.49) | DPP8DPP9DPP7GSRGNAI3 | |
| SCHEMBL31325363 | 0.97 | DPP8 (0.49) | DPP8DPP9DPP7GSRGNAI3 | |
| SCHEMBL29805332 | 0.97 | DPP8 (0.49) | DPP8DPP9DPP7GSRGNAI3 | |
| SCHEMBL29462129 | 0.97 | DPP8 (0.49) | DPP8DPP9DPP7GSRGNAI3 | |
| SCHEMBL29893154 | 0.97 | DPP8 (0.49) | DPP8DPP9DPP7GSRGNAI3 | |
| SCHEMBL30118075 | 0.91 | GSR (0.44) | DPP8DPP9DPP7GSRGNAI3 | |
| SCHEMBL16152404 | 0.91 | GNAI3 (0.62) | DPP8DPP9DPP7GSRGNAI3 | |
| SCHEMBL30799418 | 0.90 | DPP8 (0.49) | DPP8DPP9DPP7GSRGNAI3 | |
| SCHEMBL31614336 | 0.90 | DPP8 (0.49) | DPP8DPP9DPP7GSRGNAI3 | |
| SCHEMBL16117343 | 0.90 | TLR2 (0.43) | DPP8DPP9DPP7GSRGNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4482853-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA A/S (DK) | 2025-01-01 | — | — | EP | claimed |
| CN-118891273-A | Annexin A1 derived polypeptide analogs | 雷索特制药股份有限公司 | 2024-11-01 | — | — | CN | claimed |
| EP-3497114-B1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORP (KR) | 2024-10-16 | — | — | EP | claimed |
| CN-115944738-B | Application of complement C3 cracking inhibitor in preparation of medicine for treating diabetic cardiomyopathy | 华中科技大学同济医学院附属同济医院 | 2024-06-18 | — | — | CN | claimed |
| US-20230303640-A1 | EXENDIN-4 PEPTIDE ANALOGS | TXP PHARMA AG (CH) | 2023-09-28 | — | — | US | claimed |
| US-20230295255-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA APS (DK) | 2023-09-21 | — | — | US | claimed |
| WO-2023161323-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA A/S (DK) | 2023-08-31 | — | — | WO | claimed |
| EP-4200320-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA A/S (DK) | 2023-06-28 | — | — | EP | claimed |
| US-20260000626-A1 | POLYMERIC NANOPARTICLES FOR LONG ACTING DELIVERY OF A PEPTIDE AND METHODS OF MAKING AND USING THEREOF | UNIV BROWN (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250319163-A1 | TREATMENT OF TYPE 2 DIABETES MELLITUS | SANOFI SA (FR) | 2025-10-16 | — | — | US | disclosed |
| US-20250236656-A1 | MULTIMERIC POLYPEPTIDES AND USES THEREOF | Amide Technologies (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4582441-A2 | MULTIMERIC POLYPEPTIDES AND USES THEREOF | Amide Technologies (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250171515-A1 | AAV VECTORS FOR DELIVERY OF GLP-1 RECEPTOR AGONIST FUSIONS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4489770-A1 | AAV VECTORS FOR DELIVERY OF GLP-1 RECEPTOR AGONIST FUSIONS | The Trustees of the University of Pennsylvania (US) | 2025-01-15 | — | — | EP | disclosed |
| WO-2022046809-A1 | VIRAL VECTOR ENCODING GLP-1 RECEPTOR AGONIST FUSIONS AND USES THEREOF IN TREATING METABOLIC DISEASES IN FELINES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022046815-A1 | VIRAL VECTORS ENCODING GLP-1 RECEPTOR AGONIST FUSIONS AND USES THEREOF IN TREATING METABOLIC DISEASES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20080260829-A1 | Bone morphogenic proteins (bmp); cell adhesion modulating agent; peptidomimetics of cyclic peptides comprising classical cadherin cell adhesion recognition (CAR) sequences; modulate cell adhesion and improve drug delivery | NEW YORK SOCIETY FOR THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY (US) | 2008-10-23 | — | — | US | disclosed |
| CN-1406124-A | Nasal administration of cyclic peptide compositions | BASILEA PHARMACUEITCA AG (CH) | 2003-03-26 | — | — | CN | disclosed |
| EP-1237581-A1 | USE OF CATIONIC LIPIDS FOR INTRACELLULAR PROTEIN DELIVERY | Gene Therapy Systems, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001043778-A1 | USE OF CATIONIC LIPIDS FOR INTRACELLULAR PROTEIN DELIVERY | GENE THERAPY SYSTEMS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000626-A1 | POLYMERIC NANOPARTICLES FOR LONG ACTING DELIVERY OF A PEPTIDE AND METHODS OF MAKING AND USING THEREOF | VEGFA, IAPP, NPPA | DPP8 2781/4885DPP9 1118/4885DPP7 2068/4885 |
| US-20080260829-A1 | Bone morphogenic proteins (bmp); cell adhesion modulating agent; peptidomimetics of cyclic peptides comprising classical cadherin cell adhesion recognition (CAR) sequences; modulate cell adhesion and improve drug delivery | BMP1, BMP2, BMP4 | DPP8 2732/4885DPP9 2265/4885DPP7 2657/4885 |
| US-20250236656-A1 | MULTIMERIC POLYPEPTIDES AND USES THEREOF | GIPR, GRPR, SCTR | DPP8 170/4885DPP9 327/4885DPP7 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.